The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Proteome Science |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.proteomesci.com/content/9/1/68 |
| Doi | http://dx.doi.org/10.1186/1477-5956-9-68 |
| Field | Biochemistry |
| Keywords | (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12); plasma retinol-binding protein 4; RBP4; cisplatin; adamantylamine; proteomics |
| Attached files | |
| Description | Background: The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine) amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring. Methods: Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis. Results: We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials. Conclusions: RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. |
| Related projects: |